WO2019143145A1 - Composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine d2 en tant que principe actif - Google Patents

Composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine d2 en tant que principe actif Download PDF

Info

Publication number
WO2019143145A1
WO2019143145A1 PCT/KR2019/000692 KR2019000692W WO2019143145A1 WO 2019143145 A1 WO2019143145 A1 WO 2019143145A1 KR 2019000692 W KR2019000692 W KR 2019000692W WO 2019143145 A1 WO2019143145 A1 WO 2019143145A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
inflammation
hair loss
composition
skin inflammation
Prior art date
Application number
PCT/KR2019/000692
Other languages
English (en)
Korean (ko)
Inventor
이윤희
김상남
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2019143145A1 publication Critical patent/WO2019143145A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a composition for the treatment of skin inflammation containing resorcin D2 as an active ingredient. More particularly, the present invention relates to a composition for the prevention or treatment of skin inflammation or hair loss comprising resolol D2 or a salt thereof as an active ingredient, Compositions, quasi-drug compositions and cosmetic compositions.
  • Inflammation is a physiological response that protects the body from harmful environmental conditions, such as intrusion of external foreign matter such as bacteria and mechanical damage.
  • This inflammation results in a large number of polynuclear leukocytes and immune substances, and these cells are able to treat and defend by secretion of various kinds of inflammatory cell products, proteases and cytokines .
  • Enzymes such as elastase, hyalurinidase and lipoxygenase are known to be proteins and lipolytic enzymes that are produced during inflammation.
  • these actions can cause harmful damage to adjacent tissue cells and non-tissue cell components, resulting in severe tissue damage of chronic inflammation.
  • Lipid-derived signaling molecules regulate a variety of cellular processes including cell survival, apoptosis, and metabolism.
  • lipid-derived signaling molecules specialized pro-resolving lipid mediators (SPMs) are known to be endogenous lipid species involved in the natural inflammatory cycle.
  • SPMs pro-resolving lipid mediators
  • Resolvins are one of the SPMs produced from the metabolism of omega-3 essential fatty acids by lipoxygenase and other lipid regulating enzymes.
  • Immunomodulatory disorders and inflammation of the skin are a fundamental pathological mechanism of skin disease and the use of resolvin has been suggested as a treatment method.
  • the role of lipoxygenase 15, Alox15, and resolvin D2 in relation to skin homeostasis is unknown.
  • It is yet another object of the present invention to provide a method for preventing or treating skin inflammation or hair loss of a composition comprising administering to a subject a resorcin D2 or an acceptable salt thereof.
  • the present invention provides a pharmaceutical composition for preventing or treating skin inflammation or hair loss comprising resololin D2 (Resolvin D2) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the skin inflammation or depilation may be inflammation due to the low expression or deletion of the Alox15 gene.
  • the skin inflammation may be inflammation occurring in the skin fat layer.
  • the skin inflammation may be chronic skin inflammation.
  • the hair loss may be caused by inflammation of the skin fat layer.
  • the composition reduces the expression level of RIP3 (receptor-interaction serine / threonine-protein kinase 3), p-RIP3 (phosphorylated- RIP3) or ZBP1 Inflammation or hair loss.
  • RIP3 receptor-interaction serine / threonine-protein kinase 3
  • p-RIP3 phosphorylated- RIP3
  • ZBP1 Inflammation or hair loss the expression level of RIP3 (receptor-interaction serine / threonine-protein kinase 3), p-RIP3 (phosphorylated- RIP3) or ZBP1 Inflammation or hair loss.
  • the present invention provides a quasi-drug composition for preventing or treating skin inflammation or hair loss comprising resolol D2 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a cosmetic composition for preventing or ameliorating skin inflammation or hair loss comprising, as an active ingredient, resololin D2 or a cosmetically acceptable salt thereof.
  • the present invention also provides a method of preventing or treating skin inflammation or hair loss comprising administering to a subject lesolin D2 or an acceptable salt thereof.
  • the present invention also provides a method of preventing or treating skin irritation or depilation of a composition comprising administering to a subject lesolin D2 or an acceptable salt thereof.
  • composition comprising the resorcin D2 of the present invention alleviates skin inflammation, suppresses cell death, promotes hair growth as well as prevents and treats hair loss caused by inflammation of the skin fat layer, and can be usefully used as a therapeutic agent for skin inflammation disease, prevention or treatment of hair loss, quasi-drugs for improving skin irritation or promoting hair growth, and cosmetic composition.
  • FIG. 1 shows the results of (a, WT; b, Alox 15 KO) expression of Alox15 through H / E staining and immunofluorescence staining in skin such as mouse.
  • FIG. 3 shows the result of checking the hair loss phenomenon in the back skin of WT and Alox 15 knockout mice:
  • FIG. 3a is a photograph showing the hair loss phenomenon after 16 weeks, and
  • FIG. 3b is a graph quantitatively showing the cumulative hair loss occurrence rate until the 18th week Hair loss is defined as hair loss if more than 1 cm 2 is seen).
  • FIG. 5 shows results of an increase in inflammation and an increase in the expression of fibrosis markers in the Alox15 knockout mouse.
  • FIG. 5A shows the result of immunofluorescence staining of F4 / 80
  • FIG. 5B shows the result of double staining of Plin1 and Ly6C
  • 5D is a result of double staining of SMA and tdTomato
  • FIG. 6B shows the results of immunohistochemical analysis of p-RIP3, RIP3,
  • 7A is a PCA analysis of eicosanoid and derivatives thereof in the dorsal skin of mice.
  • Figure 7b shows the heat maps of 24 lipid species that are differentially regulated in Alox15 KO mice and the control group.
  • FIG. 7C shows the results of confirming the expression of skin RvD1, RvD3, 9-HODE and 13-OxoHODE in mice.
  • FIG. 8 shows the result of treating RvD2 with Alox15 KO mice.
  • Fig. 8a shows improvement of hair loss after RvD2 treatment
  • Fig. 8b-c shows H / E staining of CD11b and immunofluorescence
  • FIG. 8D shows the result of immunoblot analysis of the expression of cell death markers
  • the present inventors have found that hair loss occurs in the knockout mouse model in which lipoxygenase 15 (Alox15) is deleted and that the structure of skin is destroyed. As a result, hair follicle stem cells decrease, , And found that skin adipose tissues undergo abnormal migration to fibroblasts. Deletion of Alox15 increased infiltration of proinflammatory macrophages and increased expression of proinflammatory and skin cell death signaling genes in dorsal skin. In particular, it was confirmed that Resolvin D2 in the back skin of Alox15 knockout mouse was significantly reduced.
  • the present inventors have completed the present invention by confirming that the hair loss is improved, the hair loss is progressed, the expression of skin cell death marker is decreased, and the inflammatory index is improved.
  • the present invention provides a pharmaceutical composition for preventing or treating skin inflammation or hair loss comprising Resolvin D2 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • resorcin of the present invention refers to an inflammatory clearing lipid mediator produced by the body from omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid.
  • Resolvin D2, RvD2 of the present invention is 7S, 16R, 17S-trihydroxy-DHA (7S, 16R, 17S-trihydroxy- DHA) represented by the following formula: DHA (Docosahexaenoic acid) Lt; / RTI >
  • the skin inflammation or alopecia may be inflammation due to low expression or deletion of the Alox 15 gene.
  • the skin inflammation according to the present invention may be an inflammation occurring in the skin fat layer due to the low expression or deletion of Alox15.
  • the skin inflammation may be chronic skin inflammation.
  • hair loss of the present invention means a phenomenon in which hair completely escapes from the scalp.
  • a person undergoing hair loss has a short growing period and a long dormant hair cycle, as demonstrated in the following examples, RvD2 converts hair from resting to growing, inhibiting hair growth and wool-related growth factors It was confirmed that hair loss, which increases expression, is prevented, improved or treated.
  • the hair loss may be caused by inflammation of the skin fat layer.
  • the terms " pharmaceutically acceptable salt ", " cosmetically acceptable salt ", or " salt thereof &quot may be an acid addition salt formed by a free acid.
  • Acid addition salts can be prepared in a conventional manner, for example, by dissolving the compound in an excess amount of an aqueous acid solution and precipitating the salt with a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. It is also possible to heat an equimolar amount of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water, and then evaporate the mixture to dryness, or the precipitated salt may be subjected to suction filtration.
  • an acid or alcohol e.g., glycol monomethyl ether
  • RvD2 of the present invention can be used in the form of a pharmaceutically acceptable salt, and as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful.
  • Acid addition salts include those derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates, Dioleate, aromatic acid, aliphatic and aromatic sulfonic acids.
  • Such pharmaceutically innocuous salts include, but are not limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihalogenphosphate, metaphosphate, pyrophosphate chloride, bromide, Butyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, succinate, maleic anhydride, maleic anhydride, , Sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, Methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluene sulfonate, chlorobenzene sulfoxide But are not limited to,
  • the acid addition salt according to the present invention can be obtained by a conventional method, for example, by dissolving RvD2 in an excess amount of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile . Heating the same amount of RvD2 and an acid or alcohol in water, and then evaporating and drying the mixture, or by suction filtration of the precipitated salt.
  • a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile
  • bases can be used to make pharmaceutically acceptable metal salts.
  • the alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess amount of an alkali metal hydroxide or an alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is preferable for the metal salt to produce sodium, potassium or calcium salt.
  • the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).
  • the RvD2 of the present invention includes not only pharmaceutically acceptable salts, but also all salts, hydrates and solvates which can be prepared by conventional methods.
  • the addition salt according to the present invention may be prepared by a conventional method.
  • RvD2 may be dissolved in a water-miscible organic solvent such as acetone, methanol, ethanol, acetonitrile, etc. and added with an excess amount of an organic acid, followeded by precipitation or crystallization. Subsequently, in this mixture, a solvent or an excess acid is evaporated and then dried to obtain an additional salt, or the precipitated salt can be produced by suction filtration.
  • a water-miscible organic solvent such as acetone, methanol, ethanol, acetonitrile, etc.
  • the pharmaceutical composition containing RvD2 or a pharmaceutically acceptable salt thereof as an active ingredient may be formulated into various oral or parenteral dosage forms at the time of clinical administration, , But is not limited thereto.
  • formulations for oral administration include tablets, pills, light / soft capsules, liquids, suspensions, emulsions, syrups, granules and elixirs.
  • These formulations may contain, in addition to the active ingredient, a diluent (e.g., lactose, dextrose, (E.g., silica, talc, stearic acid and magnesium or calcium salts thereof and / or polyethylene glycols), such as, for example, water, rosin, sucrose, mannitol, sorbitol, cellulose and / or glycine.
  • a diluent e.g., lactose, dextrose, (E.g., silica, talc, stearic acid and magnesium or calcium salts thereof and / or polyethylene glycols
  • a diluent e.g., lactose, dextrose, (E.g., silica, tal
  • the tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine and may optionally contain additives such as starch, agar, alginic acid or its sodium salt A disintegrating or boiling mixture and / or an absorbent, a colorant, a flavoring agent, and a sweetening agent.
  • binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine
  • additives such as starch, agar, alginic acid or its sodium salt A disintegrating or boiling mixture and / or an absorbent, a colorant, a flavoring agent, and a sweetening agent.
  • the pharmaceutical composition containing RvD2 of the present invention or its pharmaceutically acceptable salt as an active ingredient can be administered parenterally, and parenteral administration can be carried out by injecting subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection And.
  • parenteral administration can be carried out by injecting subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection And.
  • RvD2 or a pharmaceutically acceptable salt thereof may be mixed with water or a stabilizer or a buffer to prepare a solution or suspension, which may be prepared into an ampoule or vial unit dosage form .
  • compositions may contain sterilized and / or preservatives, stabilizers, wettable or emulsifying accelerators, adjuvants such as salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances, Or may be formulated according to the coating method.
  • the dose of the compound of the present invention to the human body may vary depending on the patient's age, weight, sex, dosage form, health condition, and disease severity. In general, when referring to an adult patient weighing 60 kg, And may be 0.01 to 500 mg / day, preferably 0.01 to 500 mg / day, and may be administered once or several times a day at regular intervals according to the judgment of a doctor or pharmacist.
  • the present invention also provides a quasi-drug composition for preventing or treating skin inflammation or hair loss comprising RvD2 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • a quasi-drug composition for preventing or treating skin inflammation or hair loss comprising RvD2 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the specific contents of RvD2 are as described above.
  • Quasi-drug product used in the present invention means products that are less active than drugs, among the products used for diagnosing, treating, improving, alleviating, treating or preventing diseases of human or animal.
  • Quasi-drugs are products that are used for the purpose of treating or preventing diseases of humans or animals, products that are mild or have no direct action on the human body.
  • RvD2 of the present invention When RvD2 of the present invention is used as an active ingredient of a quasi-drug product composition, RvD2 which exhibits skin inflammation prevention or treatment, prevention of hair loss, and hair growth promoting effect can be directly added or used together with other quasi-drugs or quasi drug components, And the like.
  • the amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use.
  • the quasi-drug composition of the present invention is not particularly limited in its formulation and may be variously formulated in the form of quasi-drugs known in the art.
  • the quasi-drug composition of the present invention is used for the purpose of preventing or treating skin inflammation or hair loss, and is not particularly limited in its formulation.
  • Examples of the quasi-drug composition include softening longevity, nutritional lotion, massage cream, , A mask sheet, a gel or a skin adhesive type cosmetic composition, and may be a transdermal dosage form such as lotion, ointment, gel, cream, patch or spray.
  • the formulated quasi-drugs can be used in various forms such as scalp tonic, scalp lotion, scalp cream, scalp serum, scalp essence, scalp ampoule, scalp treatment, scalp conditioner, scalp shampoo, scalp pack, hair tonic, , Hair mousse, hair gel, hair conditioner, hair shampoo, hair conditioner, hair pack, hair treatment, eyebrow hair extender, eyelash hair extender, eyelash hair conditioner, eyelash nourishing agent, pet shampoo, pet rinse, hand cleaner, detergent soap, A wetting agent, a mask, an ointment agent, a patch or a filter filler, and includes quasi-drugs in a conventional sense.
  • the quasi-drug composition in each formulation can be blended by arbitrarily selecting other components according to the formulation of the other quasi-drugs, the purpose of use, and the like.
  • the mixing amount of the active ingredient can be appropriately determined according to the intended use (inhibition or relaxation).
  • conventional adjuvants such as thickeners, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers and the like.
  • the content of the composition is preferably 0.0001 to 10% by weight based on the total weight of the composition. If it is more than 10% by weight, the color and stability of the composition are poor. When the composition is less than 0.0001% by weight, .
  • the quasi-drug composition containing RvD2 of the present invention as an active ingredient has little toxicity and side effects to cells as confirmed by the treatment index, and thus can be useful as a quasi-drug material.
  • the present invention also provides a cosmetic composition for preventing or ameliorating skin inflammation or hair loss comprising RvD2 or a cosmetically acceptable salt thereof as an active ingredient.
  • the components included in the cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to RvD2 or its pharmaceutically acceptable salts as an active ingredient, and examples thereof include antioxidants, stabilizers, solubilizers, vitamins, , And a carrier.
  • the cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto.
  • the formulation of the present invention is a paste, cream or gel
  • an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
  • lactose When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • a spray in particular, / Propane or dimethyl ether.
  • a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
  • the formulation of the present invention is a suspension
  • a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc.
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester
  • the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
  • the present invention also provides a method of preventing or treating skin inflammation or hair loss comprising administering to a subject lesolin D2 or an acceptable salt thereof.
  • the present invention also provides a method of preventing or treating skin irritation or depilation of a composition comprising administering to a subject lesolin D2 or an acceptable salt thereof.
  • composition or cosmetic composition comprising RvD2 or an acceptable salt thereof according to the present invention as an active ingredient is useful as an agent for inhibiting the expression or deletion of the Alox15 gene and for alopecia caused by the Rox3 receptor-interactiong serine / threonine-protein kinase 3), p-RIP3 (phosphorylated-RIP3) or ZBP1 (Z-DNA binding protein 1) .
  • mice All animal tests were carried out according to regulations set by the Korea Food and Drug Administration and Yonsei University. During the experiment, the mice were fed a regular solid chow with water and maintained in a 22 ° C, 12 hour night and day cycle environment.
  • Alox15 KO mice (JAX Mice Stock # 002778, Bar Harbor, ME, USA) were purchased and reared. Male C57BL / 6 mice 5-6 weeks old were purchased from Orient Biotech and used as a normal phenotype control.
  • AdipoqCreER mice (JAX Mice Stock # 024671: B6.129-Tg (Adipoqcre / Esr1 *) 1Evdr / J) and tdTomato mice (JAX MICE Stock # 007914: B6.Cg- Gt (ROSA) 26Sortm9 (CAG-tdTomato) Hze / J) were purchased, Alox15 - / - KO mice crossed with Alox15 - was prepared adipoqCreER_tdTomato triple transgenic mice - /.
  • Cre transformation sunflower seed oil (Sigma, 50 mg / kg body weight) in which tamoxifen was dissolved in 4-week old mice was taken daily for 5 days.
  • RvD2 (Cayman) treatment 8 wk old WT mice and Alox15 KO mice were injected intraperitoneally with RvD2 at 25 ng / kg for 2 weeks once every other day.
  • a cDNA synthesis kit High-capacity cDNA Reverse Transcription Kit; Applied Biosystems, Foster City, Respectively. (IQ SYBR Green Supermix; Bio-Rad, Hercules, Calif., USA) with 100 nM cDNA in
  • mice The back skin of the mice was cut into histological sections and H / E staining or immunohistological analysis was performed with a 5- ⁇ m thick paraffin section.
  • Antibodies used for immunochemical detection were anti-15-lipoxygenase-1 antibody (Abcam), Collagen I (Abcam), Perilipin A (Cell Signaling), Keratin 14 (Cell Signaling), Keratin 15 (Cell Signaling), PDGFRA systems, Smooth muscle actin-FICT (Sigma), HMGB1 (Cell Signaling), tdTomato (Clonetech), Ly6C (Biolegend) and F4 / 80 antibody (AbD Serotec). Alexa Fluor 488, donkey anti-goat-Alexa Fluor 594, and donkey anti-Alexa Fluor 594 (ThermoFisher Scientific, Molecular Probes ) was used.
  • Missing primary antibody or common rabbit, rat, goat or mouse IgG control (Santa Cruz Biotechnology) was used as a negative control.
  • DAPI (Sigma) was used for contrast dyeing of the nuclei and the cells were visualized by Zeiss confocal laser-scanning microscope (LSM 710 META, Zeiss, Jena, Germany).
  • Tissue samples were ground (3 X 10 sec) by probe sonication in ice.
  • the cell lysates were analyzed by LC-MS-based lipid analysis to determine the lipid content of fatty acids (Lee YH et al., American Journal of Physiology, 2016; 310 (1): R55-65).
  • Lipid extraction and LC-MS / MS analysis were performed at the Pathology Department of Wayne State University.
  • Resolvin D2 ELISA Kit (Cayman Chemical) was used to measure the level of RvD2 expression in the skin.
  • Alox15 was not observed in all dermal layers of Alox15 knockout mouse (Fig. 1).
  • Alox15 was highly expressed in the dorsal skin and dermal fat layer as compared with brown adipose tissue (Fig. 2).
  • keratin 15 + follicular stem cells were reduced in Alox15 KO mice, whereas keratin 14+ cells were increased (Fig. 4).
  • the present inventors also observed histological analysis of thickening of the epidermal layer or increase of the myeloid cells in the dermal fat tissue layer. From these results, the integrity of the skin layer was destroyed by the decrease of Alox15 expression and the hair follicle growth cycle And it became abnormal.
  • the AdipoqCreER / Rosa26-loxP-stop-loxP-tdTomato system was used to track adipose cells in the dorsal skin of Alox15 knockout mice.
  • Adipocyte- expressing adipocytes in this system were labeled with the red fluorescent protein tdTomato after treatment with tamoxifen.
  • TdTomato expression was observed only in dermal adipocytes and not in myofibroblasts in the wild type control group.
  • tdTomato + cells were observed in the skin of Alox15 KO mouse, which indicates adipocytes that are differentiated into myoblasts (Fig. 5e).
  • fibroblasts are mainly surrounded by hair follicles in the dermal fat layer.
  • the expression profile of the proinflammatory gene markers (Tnfa, IL1 [beta], Emr1) and fibrogenic markers (Fibronectin Tgfb1, Tgfb3) was increased through the dorsal skin expression profile of Alox15 mice (Fig. 5f).
  • HMGB1 high-mobility group box 1 protein
  • HMGB1 is a nucleoprotein that regulates apoptosis. It moves from the nucleus to the cytoplasm and is released from the cell by the cell damage signal.
  • HMGB1 expression was confirmed, indicating that the expression of HMGB1 was highly expressed in the cytoplasm due to apoptosis of dermal cells of Alox15 KO mice (FIG. 6A).
  • Immunoblot analysis showed that phosphorylation of RIP3 (receptor-interaction serine / threonine-protein kinase 3) and expression of ZBP1 (Z-DNA binding protein 1) were increased in Alox15 KO mice (FIG. These results suggest that cell death is increased in the dorsal skin of Alox15 KO mice.
  • Alox15 The key function of Alox15 is to produce lipid mediators of arachidonic acid and other fatty acids.
  • the LC-MS / MS lipidome analysis of the skin revealed 90 lipid species and the principal component analysis (PCA) showed the lipid metabolite profile of Alox15 mouse. The lipid profile was separated by the secondary component factor (F2) of the principal component analysis, accounting for 21.47% of the total variance.
  • Cluster analysis clearly showed the skin lipid profiles of WT and Alox15 KO mice (Fig. 7A). RvD2 and 9-HODE were identified as major components in the total data, and it was confirmed that the expression of Alox15 KO mice was remarkably decreased in the dorsal skin (Fig. 7 (b), (c)).
  • Alox15 KO mice were treated with RvD2. As a result, as shown in Fig. 8, the hair began to come back to the hair loss part by RvD2 (Fig. 8A), and the integrity of the skin was restored (Fig. 8B). In addition, it was confirmed that the infiltration of CD11b + myeloma cells was reduced after treatment with RvD2 (FIG. 8c), and the cell death killing was inhibited (FIG. 8d).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine D2 en tant que principe actif. Plus spécifiquement, la présente invention concerne une composition pharmaceutique, une composition de quasi-médicament et une composition cosmétique pour la prévention ou le traitement d'une inflammation cutanée ou d'une perte de cheveux, toutes ces compositions comprenant de la résolvine D2 ou un sel de celle-ci en tant que principe actif. Une composition comprenant de la résolvine D2, selon la présente invention, atténue les effets inflammatoires cutanés, inhibe la mort cellulaire, empêche et traite la perte de cheveux provoquée par l'inflammation d'une couche de graisse dans la peau, et favorise également la pousse des cheveux, et présente ainsi un effet de réparation globale de l'intégrité de la peau, ce qui permet de l'utiliser efficacement en tant qu'agent pour traiter les maladies inflammatoires cutanées, en tant qu'agent pour prévenir ou traiter la perte de cheveux, ou en tant que quasi-médicament et composition cosmétique pour soulager une inflammation cutanée ou favoriser la pousse des cheveux.
PCT/KR2019/000692 2018-01-17 2019-01-17 Composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine d2 en tant que principe actif WO2019143145A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0006148 2018-01-17
KR1020180006148A KR102003153B1 (ko) 2018-01-17 2018-01-17 레졸빈 d2를 유효성분으로 함유하는 피부 염증 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2019143145A1 true WO2019143145A1 (fr) 2019-07-25

Family

ID=67301814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/000692 WO2019143145A1 (fr) 2018-01-17 2019-01-17 Composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine d2 en tant que principe actif

Country Status (2)

Country Link
KR (1) KR102003153B1 (fr)
WO (1) WO2019143145A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046635A4 (fr) * 2019-10-17 2023-11-22 Epi Biotech Co., Ltd. Composition comprenant un inhibiteur de la kinase rip, pour prévenir la chute des cheveux ou pour favoriser la repousse des cheveux

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102268702B1 (ko) * 2019-10-17 2021-06-24 주식회사 에피바이오텍 Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079631A1 (en) * 2011-03-25 2014-03-20 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
JP2015522535A (ja) * 2012-05-10 2015-08-06 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
KR20170122808A (ko) * 2015-03-10 2017-11-06 이엘씨 매니지먼트 엘엘씨 염증을 해소하도록 피부를 치료하고 해소촉진 경로를 자극하는 활성성분에 대해 스크리닝하기 위한 방법 및 조성물
KR20170134747A (ko) * 2015-04-16 2017-12-06 이엘씨 매니지먼트 엘엘씨 해소촉진 경로 자극제를 케라틴 표면에 전달하기 위한 단위 용량 패키지, 조성물, 및 치료 요법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079631A1 (en) * 2011-03-25 2014-03-20 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
JP2015522535A (ja) * 2012-05-10 2015-08-06 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
KR20170122808A (ko) * 2015-03-10 2017-11-06 이엘씨 매니지먼트 엘엘씨 염증을 해소하도록 피부를 치료하고 해소촉진 경로를 자극하는 활성성분에 대해 스크리닝하기 위한 방법 및 조성물
KR20170134747A (ko) * 2015-04-16 2017-12-06 이엘씨 매니지먼트 엘엘씨 해소촉진 경로 자극제를 케라틴 표면에 전달하기 위한 단위 용량 패키지, 조성물, 및 치료 요법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENE, G.: "In vitro and in vivo anti-inflammatory effect of a biotechnologically modified borage seed extract: evidence forlipid pro-resolving mediators'' implication in the enhancement of psoriatic and atopic dermatitis lesions", JOURNAL OF COSMETICS, DERMATOLOGICAL SCIENCES AND APPLICATIONS, 2015, pages 151 - 160 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046635A4 (fr) * 2019-10-17 2023-11-22 Epi Biotech Co., Ltd. Composition comprenant un inhibiteur de la kinase rip, pour prévenir la chute des cheveux ou pour favoriser la repousse des cheveux

Also Published As

Publication number Publication date
KR102003153B1 (ko) 2019-07-23

Similar Documents

Publication Publication Date Title
WO2021033829A1 (fr) Peptide ayant une activité d'amélioration de l'état de la peau et son utilisation
WO2016167527A1 (fr) Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci
KR20200039677A (ko) 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형
WO2018128515A1 (fr) Composition pharmaceutique contenant du niclosamide pour le traitement des maladies liées à des liaisons protéiques axine-gsk3
KR20010031266A (ko) 헤지호그류 폴리펩티드에 의해 상피 조직을 조절하는방법, 및 이와 관련된 제형 및 용도
WO2011152671A9 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies inflammatoires ou de maladies du système immunitaire, contenant de la ramaline
BR112012004058A2 (pt) preparação terapêutica para rinite
WO2020171285A1 (fr) Peptide pour la prévention de lésions cutanées provoquées par des polluants atmosphériques et pour la lutte contre le vieillissement, et utilisation associée
WO2019143145A1 (fr) Composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine d2 en tant que principe actif
KR20160022119A (ko) 아토피 피부염 개선, 주름 개선 및 미백활성을 갖는 불멸화 세포주 및 이의 용도
EA038943B1 (ru) Применение ингибитора mpc1 для ускорения или восстановления роста волос
WO2015030328A1 (fr) Compositions pour prévenir ou traiter des troubles cutanés allergiques, contenant les agents gpcr19 comme ingrédients actifs
WO2012020989A9 (fr) Composition pharmaceutique ou cosmétique contenant de l'acide nicotinique adénine dinucléotide phosphate ou un dérivé de celui-ci
WO2018056676A1 (fr) Composition pharmaceutique comprenant un extrait de maïs pourpre pour la prévention ou le traitement d'une maladie de la peau
WO2018070706A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser leur pousse comprenant du décanal ou un sel pharmaceutiquement acceptable de celui-ci à titre de principe actif
KR20160061945A (ko) 아토피 피부염 개선, 주름 개선 및 미백활성을 갖는 불멸화 세포주 및 이의 용도
WO2024123024A1 (fr) Composition contenant un extrait de centipeda minima pour la prévention et le traitement de l'inflammation et des maladies auto-immunes et son procédé de fabrication
KR20150018851A (ko) 피부 염증 질환의 치료 방법
JP2015529669A (ja) 脱毛症及び／又は毛髪色素脱失を治療するためのｐｅｄｆ由来のポリペプチドの使用
WO2022163989A1 (fr) Composition pour prévenir ou réduire la chute des cheveux, comprenant un gène ou une protéine de collagène
AU2021202182B2 (en) Adelmidrol for use in diseases characterized by insufficient agonism of ppar-gamma receptor
US20150352100A1 (en) Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands
KR101794935B1 (ko) 4'-o-메틸알피눔 이소플라본을 유효성분으로 포함하는 피부 질환 치료용 약학적 조성물
WO2021107381A1 (fr) Composition comprenant de l'acide férulique et des analogues de celui-ci pour prévenir et traiter des maladies cutanées causées par une mutation génétique
WO2017146341A1 (fr) Composition pour le traitement des plaies, contenant de la daphnine, et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19741256

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19741256

Country of ref document: EP

Kind code of ref document: A1